Partial and Generalized Lipodystrophy: Comparison of Baseline Characteristics and Response to Metreleptin

Lipodystrophies are extreme forms of metabolic syndrome. Metreleptin was approved in the United States for generalized lipodystrophy (GLD) but not partial lipodystrophy (PLD). The objective of the study was to test metreleptin's efficacy in PLD vs GLD and find predictors for treatment response. This was a prospective, single-arm, open-label study since 2000 with continuous enrollment. Current analysis included metreleptin treatment for 6 months...